|Description||Infectious Disease Oral Vaccines|
|Venture Round, 11/2009 |
|Series B, 12/2013 |
Ignition Venture Management
Blue Haven Initiative
|Debt, 10/2010 ||$35.1M|
|Debt, 10/2013 ||$2.5M|
PaxVax is a vaccine start-up company developing candidate oral vaccines for influenza, and key infectious diseases.
PaxVax has developed a proprietary oral vaccine technology based on a common virus called adenovirus. The technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and administration by medical personnel.
PaxVax has raised more than $50 million from investors including Ignition Partners and the Wellcome Trust, and is supported by grants from the U.S. National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID) and its Division of Acquired Immunodeficiency Syndrome (DAIDS), as well as the Bill and Melinda Gates Foundation.